Medtronic Surges with $9.76B Q1 Revenue, Up 13.7%, Driven by Strong Performance Across All Segments

01

Global Revenue: $9.756 Billion

Year-on-year increase of 13.7%

On September 1 local time, Medtronic announced its financial results for the first quarter of fiscal year 2027, ended July 31, 2026.Following last year’s highest growth in nearly a decade, Medtronic reached new heights in the first quarter of this year, achieving double-digit growth that exceeded market expectations.。

Medtronic’s global revenue in the first quarter of fiscal year 2027 reached $9.756 billion (approximately RMB 65.6 billion), a year-on-year increase of 13.7%.Q1 non-GAAP operating profit was $2.316 billion, with an operating margin of 23.7%, representing year-over-year increases of 14.9% and 10 basis points, respectively.

On that day, Medtronic surged significantly in pre-market trading, closing at $92.04, up 1.53%. Some analysts believe that,Medtronic is in the early stages of a strong product cycle that will drive further acceleration in organic revenue growth.

Medtronic also raised its fiscal 2027 organic revenue and earnings per share guidance. The fiscal 2027 organic revenue growth guidance was increased from the previous 6.75%-7.25% to7.25%‑7.75%。

Medtronic Chairman and CEO Geoff Martha stated, “We are off to a strong start in fiscal 2027. Our confidence is bolstered not only by this quarter’s impressive performance but, more importantly, by the balanced growth across our business segments and the continued increase in contributions from our emerging growth platforms.”

On the same day as the earnings release, Medtronic also officially announced two investment updates.Of this, approximately $700 million will be invested in Cornerstone Robotics, an innovative Chinese surgical robotics company., the total investment includes the portion approved for market distribution outside the United States for Cornerstone Robotics' Sentire system®Rights of the Laparoscopic Surgical Robot System.

Another strategic investment of up to $80 million was directed at Pi-Cardia, a pioneer focused on leaflet modification technologies for structural heart disease.. Medtronic thereby secured a purchase option, enabling further enhancement of its structural heart disease portfolio and advancing the development of leaflet modification technologies for complex TAVR procedures.

Q1 FY2027: Medtronic’s Divisions All Delivered Impressive Results

The cardiovascular business continued to deliver outstanding performance, with Q1 revenue reaching $3.927 billion, a year-over-year increase of 19.5%; the neuroscience portfolio generated $2.678 billion in revenue, up 10.3% year over year; the medical surgical portfolio recorded $2.279 billion in revenue, a 10.0% year-over-year increase; and the diabetes business reported $843 million in revenue, representing a 16.9% year-over-year growth.

Driven by innovation, Medtronic, the global medical device giant, is demonstrating astonishing acceleration.

Breaking down by product line, the electrophysiology therapy business generated $2.218 billion in revenue in Q1, a significant year-over-year increase of 29.5%, demonstrating strong growth momentum.

of great market concernCardiac Ablation Solutions Segment Sees 88% Surge in Q1 Revenue, The clinical application of Affera and Sphere-9 products is rapidly increasing, and PFA is gaining strong momentum in the US market.

Currently, Medtronic is continuously exploring incremental opportunities in the cardiovascular sector.

The aforementioned investment in Pi-Cardia,This is part of Medtronic's broader strategy to strengthen its position in the structural heart disease sector.Several months ago, Medtronic invested in Anteris in the TAVR field to support ongoing patient enrollment and trial execution for the global pivotal study of its integrated bio-inspired TAVR—DurAVR—for patients with severe aortic stenosis, as well as to expand production capacity.

As disclosed, Medtronic is increasing its investment in the tricuspid and mitral valve fields and will continue to prioritize and invest in the structural heart disease sector.

In the field of surgical robotics, Medtronic is also actively expanding its market to gain a competitive edge.Medtronic expects the cumulative number of procedures performed using the Hugo system to exceed 50,000 by the end of the current fiscal year; the procedure volume growth rate continues to be more than twice the industry average, and the U.S. market will expand into general surgery and gynecology. The aforementioned additional investment will also help Medtronic build a differentiated global robotics business portfolio.

Technological innovations in the medical device industry are continuously opening up new tracks and battlefields, with industry leaders pivoting to bet on high-growth future markets. Built upon a substantial revenue base and market scale, Medtronic’s strong surge is a direct manifestation of the compound interest of innovation. This giant ship of the medical device industry has found its new direction.